Novel noncontraceptive benefit seen for all intrauterine devices.
Researchers sought to analyze how pain management affects quality of life and overall survival for patients with recurrent ovarian cancer.
Risk up with diagnosis of stress-related disorders or an occurrence of stressful life events around diagnosis.
Survivors of NHL should be offered genetic counseling.
Black women with cervical cancer were less likely to receive brachytherapy and had poorer survival, suggesting brachytherapy may mediate survival outcomes.
The sNDA is supported by data from the multicenter phase 2 QUADRA trial that evaluated the safety and activity of Zejula in 463 patients.
Surgery at high-volume centers is associated with decreased local recurrence risk and improved survival for women with early-stage cervical cancer.
Mirvetuximab soravtansine is the first folate receptor alpha-targeting antibody-drug conjugate.
A new study challenges the recommended use of cotesting for cervical cancer screening.
When paired with bevacizumab, neither intraperitoneal delivery of carboplatin nor cisplatin improved outcomes for patients with advanced ovarian carcinoma compared with intravenous delivery.
The number of cervical precancers (CIN2+ cases) in the United States declined from 2008 to 2016.
More accurate biomarkers are needed to better define subgroups of patients with ovarian cancer who are most likely to benefit from late-line niraparib.
Pathogenic variants ID’d in 7.8 percent of patients with breast cancer, 14.5 percent with ovarian cancer
Coadministration of the HPV16-specific vaccine, ISA101, with chemotherapy was found to be associated with stronger tumor immunity.
Median OS was significantly improved when dendritic cell vaccination therapy was added to standard second-line chemo in platinum-sensitive, relapsed ovarian cancer.
Concurrent surgery for cancer and stress urinary incontinence was associated with significantly improved QoL for women with early endometrial neoplasms and urinary stress incontinence.
According to researchers, responses to TSR-042 were seen in subgroups of patients with disease characterized as microsatellite instability (MSI)-high and MSI-low.
Median PFS was only 2.9 months for women with advanced cervical cancer receiving the combination of atezolizumab plus bevacizumab.
A clinical benefit rate of 86% was observed in a phase 2 trial of pembrolizumab plus chemotherapy in patients with recurrent, platinum-resistant ovarian cancer.
According to researchers, responses to tisotumab vedotin were seen in women with refractory advanced cervical cancer.